Latest Trading on NASDAQ

Open 218.76
Previous Close 218.90
Today's Range
218.49 219.00
52 Week Range
87.07 219.00
Volume 174.21K
Avg. Volume (Weekly) 332.91K
Bid 218.73
Ask 218.76
Market Cap 6.86M
EPS -1.81
Shares Outstanding 31.35K
YTD High 219.00
Updated March 18, 2020

GW Pharmaceuticals PLC Sponsored ADR

U.K.-based GW Pharmaceuticals (“GW Pharma”) was formed in 1998 to develop cannabinoid based drugs. Much of its research and development efforts are focused on treatments for rare conditions stemming from epilepsy, glioma (a form of brain tumor), and schizophrenia.

No data to display.

GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom.